Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.
Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute ...
More mergers among brand-name consumer companies seem likely—following a record $2.6 trillion worth of transactions announced in the first half of 2026.
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-cash transaction values Crinetics at $85 per share and is expected to close during the current quarter, subject to customary conditions.
Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.